Clinical Trials Logo

Filter by:
NCT ID: NCT05528666 Completed - Multiple Sclerosis Clinical Trials

Risk Perception in Multiple Sclerosis

Start date: September 9, 2021
Phase:
Study type: Observational

This study was a retrospective, non-interventional, cross-sectional, multi-cohort study of patients clinically diagnosed with RMS (RRMS and SPMS). Patients were classified according to the immediate previous treatment in two groups, those who were prescribed with high efficacy treatments (HETs) and those who were prescribed with non-high efficacy treatments (non-HETs). HET include alemtuzumab, ofatumumab, ocrelizumab, natalizumab, cladribine, fingolimod and ozanimod; and non-HETs include molecules classified as with moderate or modest efficacy such as: interferons, glatiramer acetate, dimethyl fumarate and teriflunomide.

NCT ID: NCT05528549 Completed - Down Syndrome Clinical Trials

Blood Flow and Blood Pressure Investigation in Down Syndrome

FBI21
Start date: September 1, 2022
Phase: Phase 3
Study type: Interventional

Down syndrome (DS) is a chromosomal condition that occurs in approximately 1 in 800 births worldwide, and causes impairments in physical function, including a reduced work capacity (as measured by VO2peak or aerobic capacity). Work capacity is important for activities of daily living, in order to live longer, healthier lives. Reduced work capacity stems in large part from autonomic dysfunction, which has been described in individuals with DS. Individuals with DS experience reduced sympathetic and parasympathetic control, which results in alterations in resting heart rate, blood pressure, and attenuated responses to sympathoexcitatory stimuli. Autonomic dysfunction may impair the ability to regulate blood flow and blood pressure to working muscles during exercise, which may cause a mismatch between oxygen supply and demand, further compromising the already reduced work capacity observed in individuals with DS. Utilization of a large muscle mass exercise, such as lower-limb dynamic exercise (similar to walking), requires a large shift in blood flow to match metabolic demand and allows the opportunity to evaluate blood flow regulation. Conversely, examination of the large changes in pressure in response to isometric exercise (i.e., a sustained contraction), allows for examination of the exercise pressor reflex as evoked by the isometric contraction. Thus, by comprehensively evaluating blood flow and blood pressure regulation, our work will further elucidate the mechanisms that underlay the reduced work capacity in individuals with DS. Improvement of overall work capacity for a population with reduced work capacity will guide future studies and exercise interventions aimed at helping to improve independence and quality of life, ultimately allowing individuals with DS to live longer, healthier lives. Aim 1 (Dynamic Exercise): To examine the effects of an acute bout of dynamic leg kicking at both relative and absolute intensity workloads on femoral blood flow to both exercising and non-exercising muscle, in individuals with and without DS. Aim 2 (Isometric Exercise): To examine the exercise pressor response to lower limb isometric exercise in individuals with and without DS.

NCT ID: NCT05528172 Completed - Clinical trials for Corneal Edema After Cataract Surgery

A Study to Investigate the Safety and Efficacy of Ripasudil (K-321) Eye Drops After Cataract Surgery

Start date: August 4, 2022
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess the safety and efficacy of K-321 in subjects after cataract surgery

NCT ID: NCT05528094 Completed - Mental Fatigue Clinical Trials

An Exploratory Investigation of a Supplement to Support Student Learning

Start date: April 14, 2022
Phase: N/A
Study type: Interventional

In this trial, the herbal supplement (GeniusDrops) will be tested to see the effects it has on the dependent variables of interest. Participants will take the supplement twice a day for a month and respond to surveys at study baseline, midpoint, and the conclusion of the study. The findings of this study will be used for marketing materials and to inform future trials using the supplement.

NCT ID: NCT05527977 Completed - Diagnostic Error Clinical Trials

Clinical Documentation Physician Compensation Incentives

Start date: September 26, 2022
Phase: N/A
Study type: Interventional

Clinical documentation which omits significant medical details negatively affects communication among physicians and impedes the diagnostic process. Clinical documentation may be improved by using compensation incentives. Therefore, compensation incentives are a compelling mechanism to promote documentation of significant medical details to improve the diagnostic process. The investigators' proposed project will use physician compensation incentives to improve documentation of clinically significant details for six common diagnoses in outpatient general internal medicine. The investigators will choose clinically significant details which more accurately represent patient complexity, improve the diagnostic process, and have potential to improve patient outcomes. To determine whether compensation incentives improve documentation of clinically significant details, the investigators will compare physicians' baseline documentation to incentivized documentation. The purpose of the investigators' project is to improve communication of clinically significant diagnostic information among physicians, thereby reducing suboptimal treatment plans, overuse, medical error, and cognitive burden upon physicians.

NCT ID: NCT05527886 Completed - Tendon Injuries Clinical Trials

Acute Effects of Dynamic Stretching, Plyometrics, and Loading on Achilles Tendon Properties and Performance Outcomes

Start date: January 18, 2023
Phase: N/A
Study type: Interventional

The study will be looking at acute changes in Achilles tendon properties and changes in a vertical single leg hop following an exercise intervention. The three exercise interventions will be randomized and take place on separate days 1 week apart. The three exercise interventions are AAROM, slow load, and plyometrics.

NCT ID: NCT05527847 Completed - Type 2 Diabetes Clinical Trials

Peers EXCEL Trial to Improve Glycemic Control

Start date: February 13, 2023
Phase: N/A
Study type: Interventional

The purpose of the study is to gather input about the value of adding a newly developed diabetes self-management program to an existing diabetes self-management program. Participants will self-identify as African-American/Black with type 2 diabetes, and prescribed a diabetes medication. Participants can expect to be in the study for 6 months.

NCT ID: NCT05527834 Completed - Pharmacokinetics Clinical Trials

Food Effect on Ceftibuten/VNRX-7145 in Healthy Participants

Start date: September 13, 2022
Phase: Phase 1
Study type: Interventional

This is an open label, two period (fasted and fed), crossover study in up to 3 cohorts of 12 healthy adult participants per cohort (up to 36 participants in total). The pharmacokinetics (PK) of the inactive prodrug VNRX-7145, its active parent drug VNRX-5236, and ceftibuten will be evaluated after a single oral dose of ceftibuten/VNRX-7145.

NCT ID: NCT05527483 Completed - Prostate Cancer Clinical Trials

Digital PET/CT Using [Ga-68]PSMA vs. [F-18]NaF for Evaluation of Osseous Metastatic Involvement in Prostate Cancer Patients

Start date: April 21, 2022
Phase:
Study type: Observational

The purpose of this study is to evaluate a radioactive diagnostic study drug, which is called Gallium-68 Prostate Specific Membrane Antigen ([Ga-68]PSMA) for detection of bone metastasis in patients with prostate cancer. For imaging the investigators will use a FDA approved imaging technology, digital Positron Emission Tomography (PET/CT). The investigators would like to know if digital PET/CT using [Ga-68]PSMA provides accurate information about the extent of bone metastases. Therefore, the investigators will compare[Ga-68]PSMA PET/CT with Flourine-18 [F-18] Sodium Fluoride (NaF), which is a high resolution bone scan. [F-18]NaF is FDA approved and the reference standard for evaluating the presence of bone metastases.[Ga-68]PSMA is an investigational (experimental) drug that works by binding to Prostate Specific Membrane Antigen, which is overexpressed in prostate cancer. [Ga-68]PSMA is experimental because it is not approved by the Food and Drug Administration (FDA) at University Hospitals. However, FDA approval has been obtained for this study protocol by an Investigational New Drug (IND) application.

NCT ID: NCT05527327 Completed - Obesity Clinical Trials

Pannus Retraction for Ultrasound Evaluation of the Obese Gravida: A Pilot Study

Start date: September 16, 2022
Phase: N/A
Study type: Interventional

Pregnancies complicated by obesity have an increased risk of multiple pregnancy complications, including structural fetal anomalies. Therefore, maternal obesity (BMI ≥30 kg/m2) is an indication for a detailed anatomic ultrasound examination. Ultrasound is a critical tool for the detection of congenital anomalies; however, obesity makes ultrasound examinations technically challenging. The primary objective of this ambidirectional cohort pilot study is to evaluate whether utilization of a pannus retractor is associated with increased rates of detailed anatomic ultrasound completion amongst pregnant patients with a body mass index (BMI) greater than or equal to 40 kg/m2. Retrospective data will be collected for 100 patients with a BMI of 40 kg/m2 or greater to assess the baseline rate of completion of 16 components of the detailed anatomic survey prior to the intervention. We plan to enroll 20 patients into a prospective pilot to the intervention arm. The intervention is placement of an adhesive medical device, the traxi® Panniculus Retractor (Laborie, Portsmouth, New Hampshire), which was developed for pannus retraction during cesarean section. Adequacy of anatomic ultrasound completion will be based upon 16 pre-defined views from the anatomic survey. Ultrasound completion rates from the prospective cohort of participants that undergo ultrasound evaluation using a pannus retractor will be compared to a historical cohort without pannus retractor use. We hypothesize that use of a pannus retractor for pregnant participants with BMI greater than or equal to 40 kg/m2 increases the rate of anatomical ultrasound completion.